[go: up one dir, main page]

MX2018016091A - Composiciones de fosfolipidos. - Google Patents

Composiciones de fosfolipidos.

Info

Publication number
MX2018016091A
MX2018016091A MX2018016091A MX2018016091A MX2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A MX 2018016091 A MX2018016091 A MX 2018016091A
Authority
MX
Mexico
Prior art keywords
compositions
extract
modified
egg yolk
phospholipid compositions
Prior art date
Application number
MX2018016091A
Other languages
English (en)
Inventor
Hudson Colleen
Kobr Lukas
F Miknis Gregory
Monfregola Luca
Jirkovsky Pavel
Milada Zboncakova
Duex Jason
Kandasamy Pitchaimani
Staszak-Jirkovsky Jakub
Original Assignee
Machavert Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Machavert Pharmaceuticals Llc filed Critical Machavert Pharmaceuticals Llc
Publication of MX2018016091A publication Critical patent/MX2018016091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2221/00—Applications of separation devices
    • B01D2221/10—Separation devices for use in medical, pharmaceutical or laboratory applications, e.g. separating amalgam from dental treatment residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se describen composiciones que implican un extracto de yema de huevo modificada para uso como un agente anti-cáncer efectivo. El extracto de yema de huevo modificada implica fracciones 5 específicas de fosfatidilcolinas y esfingomielinas modificadas y producidas de una síntesis química aplicada al extracto que produce un efecto benéfico en la inhibición del crecimiento de células cancerosas. También se describen métodos para administrar estas composiciones.
MX2018016091A 2016-06-29 2017-06-29 Composiciones de fosfolipidos. MX2018016091A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662356189P 2016-06-29 2016-06-29
US201662356197P 2016-06-29 2016-06-29
PCT/US2017/039894 WO2018005735A1 (en) 2016-06-29 2017-06-29 Phosopholipid compositions

Publications (1)

Publication Number Publication Date
MX2018016091A true MX2018016091A (es) 2019-09-16

Family

ID=60785317

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016091A MX2018016091A (es) 2016-06-29 2017-06-29 Composiciones de fosfolipidos.

Country Status (13)

Country Link
US (4) US10493086B2 (es)
EP (1) EP3478296A4 (es)
JP (1) JP2019520384A (es)
KR (1) KR20190022796A (es)
CN (1) CN109414446A (es)
AU (1) AU2017290724A1 (es)
BR (1) BR112018077350A2 (es)
CA (1) CA3029419A1 (es)
IL (1) IL263838A (es)
MX (1) MX2018016091A (es)
RU (1) RU2019102212A (es)
SG (1) SG11201811776WA (es)
WO (1) WO2018005735A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109946276B (zh) * 2019-03-25 2021-04-30 遵义师范学院 一种双光子荧光探针的用途
CN111454289A (zh) * 2019-11-08 2020-07-28 苏州东南药业股份有限公司 一种二油酰磷脂酰胆碱的制备方法
CN115364111B (zh) * 2021-05-17 2024-04-02 中国医学科学院基础医学研究所 甘油磷脂类化合物在治疗肿瘤中的用途
US20250152611A1 (en) * 2022-01-19 2025-05-15 President And Fellows Of Harvard College Immunomodulatory lipids and uses thereof
CN114894910B (zh) * 2022-03-18 2023-10-20 重庆医科大学附属第一医院 1-棕榈酰-2-花生四烯酰-sn-甘油-3-磷酸胆碱检测试剂的新用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US66354A (en) * 1867-07-02 Know all men by these presents
DE3777640D1 (es) 1986-11-28 1992-04-23 The Liposome Co.,Inc., Princeton, N.J., Us
CZ280686B6 (cs) 1992-04-07 1996-04-17 Tomáš Vojkovský N-acylované fosfolipidy typu 1-0-alkyl-sn-glycero -3-fosfoethanolaminů a způsob jejich semisyntetické přípravy a použití
US6602861B1 (en) 1992-04-16 2003-08-05 Research Corporation Technologies, Inc. Acylated phospholipid drugs
CZ282139B6 (cs) 1995-04-03 1997-05-14 Jindřich Rndr. Drsc. Kára Způsob výroby přípravku s dieteticko-preventivním a léčebným účinkem na bázi vaječných l-O-alkyl-2-acyl-fosfatidylethanolaminů
CN1516592A (zh) 2001-06-18 2004-07-28 �����Ǽ���&������Դ���޹�˾ 用于预防和/或治疗心血管疾病、关节炎、皮肤癌、糖尿病、经前综合症和透皮转运的磷虾和/或海产提取物
EP1426053A1 (en) * 2002-12-03 2004-06-09 Fresenius Kabi Deutschland GmbH Use of amphiphilic lipids for reducing tumor metastasis
CA2534241C (en) 2003-07-31 2012-05-29 The Board Of Regents Of The University Of Texas System Compositions and methods for treating, preventing and/or ameliorating cancers, the onset of cancers or the symptoms of cancers
PL1871399T3 (pl) 2005-04-18 2011-09-30 Sc Dicophar Zastosowanie lecytyny jako leku w leczeniu łuszczycy
WO2012088414A1 (en) * 2010-12-23 2012-06-28 Ludwig Institute For Cancer Research Ltd. Liposomal formulation of nonglycosidic ceramides and uses thereof
PL217384B1 (pl) * 2012-02-06 2014-07-31 Univ Przyrodniczy We Wrocławiu Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
WO2015104284A1 (en) * 2014-01-08 2015-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination

Also Published As

Publication number Publication date
RU2019102212A (ru) 2020-07-29
IL263838A (en) 2019-01-31
BR112018077350A2 (pt) 2019-04-09
US12263181B2 (en) 2025-04-01
WO2018005735A1 (en) 2018-01-04
AU2017290724A1 (en) 2019-01-17
US20220409641A1 (en) 2022-12-29
JP2019520384A (ja) 2019-07-18
WO2018005735A9 (en) 2018-02-01
EP3478296A1 (en) 2019-05-08
CA3029419A1 (en) 2018-01-04
US20180028545A1 (en) 2018-02-01
US20200046744A1 (en) 2020-02-13
CN109414446A (zh) 2019-03-01
KR20190022796A (ko) 2019-03-06
US10493086B2 (en) 2019-12-03
EP3478296A4 (en) 2020-03-25
US20180000850A1 (en) 2018-01-04
SG11201811776WA (en) 2019-01-30
US11433085B2 (en) 2022-09-06

Similar Documents

Publication Publication Date Title
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2024012899A (es) Metodos y composiciones relacionadas con crispr/cas para el tratamiento de beta hemoglobinopatias
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
MX2024001192A (es) Anticuerpos anti gen 3 de activacion linfocitica (lag-3) y metodos para usarlos.
DOP2019000163A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
MX2021006531A (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
BR112019011450A2 (pt) células naturais killer modificadas e uso das mesmas
MX2018016091A (es) Composiciones de fosfolipidos.
BR112018067679A2 (pt) células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso
MX389700B (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2018003542A2 (es) Anticuerpo anti-garp
CO2020006865A2 (es) Composiciones y métodos para el agotamiento de células cd5+
MX2017008875A (es) Anticuerpos biespecificos contra cd3 y cd20.
MX394497B (es) Nanoportadores sintéticos tolerogénicos y macromoléculas terapéuticas para efectos farmacodinámicos reducidos o intensificados.
GT201500248A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
UY36224A (es) Compuestos tricíclicos de imidazo-pirimidinona
MX378386B (es) Composiciones antiirritantes sinérgicas de taurina y aloe.
GT201400043A (es) Imidazopiridazinas sustituidas con amino
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
PE20151759A1 (es) Imidazopiridazinas sustituidas
DOP2015000298A (es) Compuestos nuevos para el tratamiento del cáncer